Table 1 Baseline characteristics of the 55 patients at infliximab initiation
Variable | N (%) [IQR] |
|---|---|
Age at start of infliximab, mean (years, min/max) | 47 (18–80) |
Sex (men/women) | 27/28 (49/51) |
Ethnicity | |
Caucasian Maghrebis West-Indies | 39 (71) 8 (14.5) 8 (14.5) |
Median disease duration (median, IQR) | 45 [14–108] |
Median number of involved organs (IQR) | 1 [1–2] |
Main involved organs | |
Lungs (stages II to IV) Central nervous system Lymph nodes Joints Bones Liver Eye(s) Skin Muscles Spleen Hypercalcemia Kidney(s) Peripheral nervous system Gut Heart Ear-nose-throat | 16 (29) 14 (25.5) 10 (18) 8 (14.5) 8 (14.5) 8 (14.5) 6 (11) 5 (9) 5 (9) 5 (9) 3 (5.5) 3 (5.5) 3 (5.5) 2 (3.5) 2 (3.5) 1 (2) |
Median number of previous treatment lines (IQR) | 2 [1–3] |
Previous immunosuppressive treatments | |
Steroids Methotrexate Cyclophosphamide Mycophenolate mofetil Azathioprine Hydroxychloroquin Others | 47 (85) 23 (42) 11 (20) 10 (18) 6 (11) 6 (11) 4 (7) |